Overview We are a biopharmaceutical company with a mission of pioneering medicines that transform patients lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA (sotagliflozin): We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM, and are conducting the SONATA-HCM pivotal Phase 3 clinical trial of...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001062822-26-000050 | EDGAR | 49K words |
| 2025-03-07 | 2024-12-31 | 0001062822-25-000013 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001062822-24-000008 | EDGAR | — |
| 2023-03-03 | 2022-12-31 | 0001062822-23-000007 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001062822-22-000005 | EDGAR | — |
| 2021-03-12 | 2020-12-31 | 0001062822-21-000013 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001062822-20-000015 | EDGAR | — |
| 2019-03-15 | 2018-12-31 | 0001062822-19-000007 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001062822-18-000008 | EDGAR | — |
| 2017-03-06 | 2016-12-31 | 0001062822-17-000013 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001062822-26-000117 | EDGAR | — |
| 2025-11-06 | 2025-09-30 | 0001062822-25-000054 | EDGAR | 14K words |
| 2025-08-06 | 2025-06-30 | 0001628280-25-038340 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001062822-25-000029 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001062822-24-000060 | EDGAR | — |
| 2024-08-02 | 2024-06-30 | 0001062822-24-000046 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001062822-24-000024 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001062822-23-000058 | EDGAR | — |
| 2023-08-04 | 2023-06-30 | 0001062822-23-000047 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001062822-23-000024 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001062822-22-000042 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001062822-22-000035 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001062822-26-000112 | EDGAR | — |
| 2026-03-05 | 0001062822-26-000047 | EDGAR | 2K words |
| 2026-02-02 | 0001193125-26-033793 | EDGAR | — |
| 2026-01-29 | 0001193125-26-029514 | EDGAR | — |
| 2025-11-10 | 0001193125-25-274383 | EDGAR | — |
| 2025-11-06 | 0001193125-25-270020 | EDGAR | — |
| 2025-11-06 | 0001062822-25-000049 | EDGAR | — |
| 2025-08-06 | 0001062822-25-000042 | EDGAR | — |
| 2025-07-28 | 0001062822-25-000037 | EDGAR | — |
| 2025-07-03 | 0001062822-25-000035 | EDGAR | — |
303 total filings indexed. 271 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001062822 |
| Ticker | LXRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.lexpharma.com |
| Listed | 2000-04-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/LXRX (~200 tokens, structured JSON with cryptographic provenance)